English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Hutchison MediPharma Starts Phase III Trial of Cancer Drug

Dec. 15, 2014

On December 15, 2014 HMP announced that it has initiated FRESCO, a Phase III registration study in colorectal cancer (“CRC”) patients in China for fruquintinib (HMPL-013), its investigational small molecule, which selectively inhibits vascular endothelial growth factor receptors (“VEGFR”). 

In October 2013, HMP entered into a licensing, co-development and commercialisation agreement in China with Eli Lilly in a deal worth up to $86.5 million in upfront and milestone payments.